Profiling the combination of bupropion and dextromethorphan as a treatment option for major depressive disorder.
Expert review of neurotherapeutics September 1, 2024 Joseph Blanco, Pamela Quimbaya, Manuel Mena et al.
A review of the neurobiology of major depressive disorder and the pharmacology, efficacy, safety, and tolerability of dextromethorphan hydrobromide combined with bupropion hydrochloride (Auvelity®) for adults. The combination is an approved alternative for MDD, usable as a first-line therapy, as a second option after failed remission with a serotonin-targeting agent, and for treatment-resistant depression. Clinicians' familiarity with both drugs may increase acceptability, and further research into other indications, including addiction disorders, may yield additional benefits. The review is based on observational studies, clinical trials, and other secondary studies from systematic literature searches.